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Bene®cial effects of interleukin-10 therapy and lower
endogenous interleukin-10 formation compared with
atopic dermatitis and cutaneous T cell lymphomas
indicated that interleukin-10 is a key cytokine in
psoriasis. The interleukin-10 promoter is highly poly-
morphic, with two informative microsatellites, inter-
leukin-10.G and interleukin-10.R. In order to
understand whether interleukin-10 itself is a predis-
posing gene for the psoriasis susceptibility we ana-
lyzed interleukin-10 promotor polymorphism in
patients. The distribution of interleukin-10.G and
interleukin10.R microsatellite alleles did not vary
between patients (n = 78) and healthy controls
(n = 80). In addition, when the psoriasis patients
were strati®ed according to age of onset (younger
than 40 y of age, or age 40 and older), no difference
in allele distribution was observed; however, a clear
differential distribution was revealed at the
interleukin10.G locus when patients were strati®ed
according to whether they had a positive family his-
tory of psoriasis (p = 0.04). This difference was due
to an over-representation of the interleukin10.G13
allele in those patients with familial disease (40.4% vs
19.6%, Chi-square = 7.292, p = 0.007). The positive
association of allele interleukin10.G13 with familial
psoriasis was especially true when patients with an
early onset (< 40 y of age) of the disease were com-
pared with those patients with early onset against a
nonfamilial background (39.6% vs 14.5%, Chi-
square = 8.959, p = 0.003). Patients with age-of-
onset of less than 40 were 4-fold [odds ratio = 3.85
(1.55±9.62)] more likely to have a psoriatic family
background if they carried this interleukin10.G13
allele. These data suggest that the interleukin-10
locus contributes to the heritability of psoriasis
susceptibility. Key words: cytokines/genetic/interleukins/
polymorphism/psoriasis. J Invest Dermatol 116:975±978,
2001
P
soriasis is considered to be a T cell-dependent (auto)-
immune disease (Valdimarsson et al, 1986). The
demonstrated overexpression of several proin¯ammatory
cytokines, in particular type 1, is considered to be
responsible for the initiation, maintenance, and reoccur-
rence of the skin lesions (reviewed in Bos and De Rie, 1999). In
contrast, we recently found that the cutaneous mRNA expression
of the anti-in¯ammatory cytokine interleukin (IL) -10 is
signi®cantly lower in psoriasis than in other in¯ammatory
dermatoses, such as atopic dermatitis and cutaneous T cell
lymphomas (Asadullah et al, 1998). Our results correspond well
with ®ndings regarding low cutaneous IL-10 protein expression, as
determined by immunohistochemistry (Nickoloff et al, 1994) and
by measurement in suction blister ¯uid (Mussi et al, 1994) in
psoriatic patients.
Several lines of evidence support the hypothesis that relative IL-
10 de®ciency might be a central phenomenon and that IL-10 is a
key cytokine in psoriasis (reviewed in Asadullah et al, 1999c): (i)
Various effective antipsoriatic treatment modalities, e.g., ultraviolet
radiation or calcitriol therapy, increase IL-10 production by several
cell types. (ii) Cyclic adenosine monophosphate-elevating drugs
upregulate IL-10 expression. Interestingly, there are sporadic
reports that these substances improved psoriasis. (iii) Inhibitors of
the b-adrenergic receptor pathway or cyclooxygenase may lead to
an exacerbation of psoriasis. These drugs diminish intracellular
cyclic adenosine monophosphate formation, presumably associated
with decreased IL-10 release. (iv) Direct support of a type 1
cytokine pattern (i.e., inhibition of IL-10 secretion) by interferon-
a or -g application as well as interferon-elevating drugs, such as
lithium are also known to provoke or to exacerbate psoriasis. (v)
Pregnancy often leads to the depression of type 1 cytokines, and the
majority of psoriatic women who become pregnant experience an
improvement in their disease activity. (vi) Calcipotriol and
glucocorticoids increase IL-10 receptor expression. It might be
speculated that this leads to an enhancement of the IL-10
susceptibility contributing to the antipsoriatic activity of these
compounds. The key role of IL-10 in psoriasis is further supported
by the bene®cial effects of IL-10 therapy recently reported by us
and others. So one pilot and two phase-2 trials with subcutaneous
IL-10 administration over 3±7 wk in patients with moderate to
severe psoriasis showed very promising results (Asadullah et al,
1998, 1999a; Reich et al, 1998).
The IL-10 de®ciency in psoriasis is particular remarkable as the
IL-10-inducing cytokine tumor necrosis factor-a was found to be
signi®cantly overexpressed in psoriasis (Kristensen et al, 1993;
Bonifati et al, 1994; Ettehadi et al, 1994; Asadullah et al, 1999b),
arguing against an insuf®cient stimulation, and might rather be the
result of a genetic predisposition to ``low IL-10 secretion''.
Genetic factors are likely to be of fundamental importance in the
expression of the disease. This is supported by numerous family,
twin, and HLA allotype studies, which gave clear evidence of a
heritable component (reviewed in Bos and De Rie, 1999). In fact a
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linkage between certain HLA antigens and psoriasis has been
reported. A high proportion of patients with type 1 psoriasis (onset
before the age of 40 y) are carriers of HLA Cw6, B57, and DR7
and show a positive family history. Moreover, it has been recently
reported that a tumor necrosis factor-a promotor polymorphism is
associated with juvenile onset of psoriasis (HoÈhler et al, 1997; Reich
et al, 1999), although this was not con®rmed in another study
(Jacob et al, 1999).
The IL-10 promoter is highly polymorphic, with two informa-
tive microsatellites, IL10.G and IL10.R (Eskdale and Gallagher,
1995; Eskdale et al, 1996) and three commonly used point
mutations (Eskdale et al, 1997a; Turner et al, 1997). Given the
importance of IL-10 in the immunopathology and treatment of
psoriasis, we felt it was important to understand whether there was
evidence to suggest that IL-10 itself is a predisposing gene for
psoriasis susceptibility. A preliminary study of the IL-10 locus in
psoriasis (Reich et al, 1999) examined one particular promoter
point mutation, but found no association with disease. In the
present report, we have used the highly informative microsatellite
markers to more ef®ciently address the question of whether the
IL-10 locus contributes to susceptibility to psoriasis.
SUBJECTS AND METHODS
Patient samples Peripheral blood was obtained from patients and
controls, and germline DNA was extracted by standard means. German
Caucasian patients (n = 80), unrelated to one another and with a
con®rmed diagnosis of psoriasis vulgaris, were examined. Patients were
considered to have ``early onset'' psoriasis if disease onset was at age
younger than 40 y (n = 55) and ``late onset'' psoriasis if age of onset was
after their fortieth birthday (n = 19); in six cases, age of onset could not
be con®rmed. In addition, patients were considered to have ``familial''
psoriasis if they have one or more ®rst- or second-degree relative
af¯icted with the condition (n = 26), or to have ``sporadic'' psoriasis if
this was not the case (n = 46); in eight cases this information could not
be con®rmed. Of those patients with ``early onset'' psoriasis, some were
also ``familial'' (n = 24, i.e., typical type 1 psoriasis) and some were
sporadic (n = 31). German Caucasian healthy volunteers (n = 90) served
as a control group. Control individuals were healthy and unrelated to
one another. They did not have a ®rst- or second-degree relative with
psoriasis.
Genotyping at the IL-10 microsatellites DNA was prepared from
white-cell pellets using the ``DNA-Fast'' kit from Epicentre
Technologies (Cambridge, U.K.). Genotyping at the IL10.G and IL10.R
microsatellites was performed as previously described in detail (Eskdale
and Gallagher, 1995; Eskdale et al, 1996, 1997a). In addition, full details
of primers and reaction conditions are present in the Genome Data Base
entry for the human IL-10 gene. Examples of IL10.G and IL10.R
genotyping gels are shown in Fig 1.
Statistical analysis The allelic distribution between two whole
populations (for example, between psoriasis patients and controls, or
between those patients with familial psoriasis or not) was compared using
the Monte Carlo simulation, and the freely available ``CLUMP'' software
of Sham and Curtis (1995). This technique has been developed
speci®cally to examine disease associations at multiallelic loci. It uses a
Monte Carlo approach by measuring the difference in allele frequencies
between the two groups and then generates multiple simulated datasets
to see how many times the observed difference might be generated by
chance if the frequencies were in fact the same. In so doing, it generates
the ``T4'' statistic, which measures the overall difference in frequencies
of all alleles simultaneously. Although this is generated in the same way
as conventional chi-square values, the use of the Monte Carlo approach
to assess empirical signi®cance avoids the need for a Bonferonni
correction and the problems of dealing with rare alleles (D.Curtis,
personal communication). p < 0.05 was taken as signi®cant. In some
cases, individual alleles were compared by 2 3 2 Chi-square analysis
using Minitab software. Odds ratios and 95% con®dence intervals were
calculated on the ``Simple Interactive Statistical Analysis (SISA)
homepage: http://home.clara.net/sisa/index.htm
RESULTS
IL-10 microsatellite alleles do not contribute to overall
psoriasis susceptibility The distribution of IL10.R and IL10.G
alleles in psoriasis patients and normal controls is shown in Table I.
No difference in allele distribution was observed overall at either
locus (Monte Carlo simulation), nor was any individual allele
differentially represented between the patient and control groups.
In addition, when we examined the distribution of IL10.G and
IL10.R alleles in relation to age of onset, there was no difference
between the ``early'' and ``late'' onset groups.
IL10.G13 microsatellite allele is over-represented in familial
psoriasis In addition to comparing the distribution of IL-10
locus alleles between patients and controls, we also considered the
question of whether the IL-10 locus was important when patients
were considered as having ``sporadic'' disease (i.e., no family history
of psoriasis) or ``familial'' disease (i.e., a clear family history of
psoriasis). As shown in Table II, this was the case. Patients with
Figure 1. Typical gels showing the IL10.R and IL10.G
microsatellite alleles. Typical sequencing gels for IL10.R (left panel)
and IL10.G (right panel). For IL10.R, lanes 1±10 typed as: 2/3, 2/3, 3/3,
2/2, 2/2, 2/2, 2/4, 2/2, 2/3, 2/3, respectively. For IL10.G, lanes 1±10
typed as: 9/14, 9/12, 13/14, 9/11, 9/9, 9/9, 9/9, 9/13, 7/14, 9/13,
respectively.
Table I. Distribution of IL10.G and IL10.R alleles in
psoriasis patients and normal individualsa
Allele
Normal
controls
Psoriasis
patients
(n = 90) (n = 80)
IL10.G1 0 (0.00) 0 (0.00)
IL10.G2 0 (0.00) 0 (0.00)
IL10.G3 0 (0.00) 0 (0.00)
IL10.G4 0 (0.00) 0 (0.00)
IL10.G5 0 (0.00) 0 (0.00)
IL10.G6 0 (0.00) 0 (0.00)
IL10.G7 7 (3.89) 4 (2.56)
IL10.G8 8 (4.44) 10 (6.41)
IL10.G9 61 (33.89) 44 (28.21)
IL10.G10 13 (7.22) 11 (7.05)
IL10.G11 18 (10.00) 12 (7.69)
IL10.G12 9 (5.00) 10 (6.41)
IL10.G13 49 (27.22) 42 (26.92)
IL10.G14 15 (8.33) 19 (12.18)
IL10.G15 0 (0.00) 4 (2.65)
(n = 88) (n = 77)
IL10.R1 0 (0.00) 0 (0.00)
IL10.R2 130 (73.86) 129 (83.77)
IL10.R3 43 (24.43) 24 (15.58)
IL10.R4 2 (1.14) 1 (0.65)
IL10.R5 1 (0.57) 0 (0.00)
aIL10.G and IL10.R alleles were visualized and de®ned as described in the text,
assuming no null alleles. The numbers of alleles observed are shown, with the pro-
portion in parenthases. A comparison of these two populations using the Monte
Carlo simulation for alleles 7±15 showed that the two populations did not vary in
their allelic distribution. Alleles IL10.G1 to IL10.G6 were not represented in any
populations tested here. Similarly, comparison of the IL10.R alleles showed no dif-
ference between patients and controls.
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familial psoriasis had a different distribution of IL10.G alleles from
those with sporadic psoriasis (Monte Carlo simulation, p = 0.04),
such that the IL10.G13 allele was over-represented in those with
inherited disease (Chi-square = 7.292, p = 0.0069). The carriage
of IL10.G13 (i.e., the presence of one or more copies of the allele)
was correspondingly elevated in patients with familial psoriasis; 17
of 26 familial patients were IL10.G13+, whereas only 17 of 46
sporadic psoriasis patients carried this allele [odds ratio = 3.22
(1.17±8.81), p = 0.02]. IL10.G allele distribution in the sporadic
disease group was not different from that seen in the controls,
thereby con®rming that it is indeed the patients with inherited
psoriasis who demonstrate skewed IL10.G allele distribution (not
shown). IL10.R locus alleles were not different between the two
subgroups of psoriasis patients.
The differential distribution of IL10.G alleles was emphasized
when the ``early'' psoriasis patients were analyzed with respect to
whether they had ``familial'' or ``sporadic'' disease. These two
groups varied in their distribution of IL10.G alleles (p = 0.025,
Monte Carlo simulation), with an enhanced over-representation of
the IL10.G13 allele in the familial group (39.6% vs 14.5%, Chi-
square = 8.959, p = 0.0028). These patients also showed a simi-
larly elevated carriage of the IL10.G13 allele, with enhanced
signi®cance; 15 of 24 familial patients were IL10.G13+, whereas
only eight of 31 sporadic psoriasis patients carried this allele [odds
ratio = 2.82 (1.51±15.18), p = 0.006].
DISCUSSION
IL-10 is considered to be a key cytokine in the pathogenesis of
psoriasis. When we examined known polymorphic microsatellite
markers in the human IL-10 promoter in psoriasis patients, no
difference was noted in comparison with the control group. This
was true of both markers utilized, IL10.G and IL10.R. In addition,
when the psoriasis patients were strati®ed according to age of onset
no difference in allele distribution was observed; however, a clear
differential distribution was revealed when patients were strati®ed
according to whether they had a positive family history of psoriasis.
In this case, allele IL10.G13 was positively associated with familial
psoriasis and this was also true when younger patients were
considered ± patients with age-of-onset of less than 40 were 3-fold
more likely to have a psoriatic family background if they carried
this allele. Thus, it appears that the IL-10 locus contributes to the
genetic background in familial psoriasis.
Genetic markers in cytokine genes are becoming widely used in
studies of immune-mediated disease and it is becoming apparent
that they can be markers of overt susceptibility and of disease
severity (reviewed in Bidwell et al, 1999). In this study we have
demonstrated that an important immunologic gene (IL-10), whose
product is known to be dysregulated in psoriasis, is in fact
genetically marked within a subpopulation of psoriasis patients.
This situation is reminiscent of that found in systemic lupus
erythematosus, where the same locus (IL10.G microsatellite) shows
signi®cant allele skewing in patients vs controls. This has been
observed in patients from the U.K. (Eskdale et al, 1997b), Mexico
(Mehrian et al, 1998), and Italy (D'Alfonso et al, 2000). Indeed, in
the U.K. and Italian studies, it was the same allele that was
associated with systemic lupus erythematosus, namely IL10.G13. It
is, therefore, unlikely to be a coincidence that it is this same
IL10.G13 allele that has been highlighted by this study on psoriasis.
Our recent investigation of the relationship between IL10.G
alleles and IL-10 secretion from lipopolysaccharide-stimulated
peripheral blood (Eskdale et al, 1998), however, failed to demon-
strate a role for the IL10.G13 allele in this context. In agreement
with this we observed only a tendency of diminished IL-10
formation capacity in psoriatic patients, but not a statistical
signi®cant difference (Asadullah et al, 1998). Although it has been
shown that genetic relationships between cytokine alleles and
secretion may vary in patient groups compared with normal groups
(Koss et al, 1999), the possibility must be considered that the
dysregulation of IL-10 seen in psoriasis patients (and from which
this study was launched), and the association between an IL-10
locus gene marker and the disease reported here are complementary
rather than related. Of course, this allele may well be of importance
in alternative pathways of IL-10 regulation, but if IL10.G13 is not
associated with differential IL-10 secretion then it is likely that this
allele is associated with both psoriasis and systemic lupus
erythematosus, through linkage disequilibrium with a novel
functional element yet to be de®ned. Recently, several new
single-nucleotide polymorphisms have been de®ned in the human
IL-10 locus (D'Alfonso et al, 1999), but none of these was
speci®cally linked to IL10.G13. Furthermore, the complex
haplotypic nature of the IL-10 locus (Eskdale et al, 1999) placed
the IL10.G13 on at least two frequent haplotypes. Both these
observations support the hypothesis that any functional element
linked to this allele may in fact lie outside the IL-10 locus per se. If
true, this would implicate IL-10 as a disease modifying gene in
psoriasis rather than a disease-causing gene.
While interesting, the studies reported here represent a ®rst step
in investigating whether a genetic relationship truly exists between
the human IL-10 gene and psoriasis susceptibility and/or
heritability. Further investigations necessary to explore fully the
impact of IL-10 polymorphism on psoriasis susceptibility should
include analyses of psoriatic families (Jacob et al, 1999) and
correlation analyses between the IL-10 secretion capacity and the
IL-10 promoter genotype in psoriatic (as opposed to normal)
individuals.
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